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Biotech industry is characterized by unique elements as the companies operate in high risk 
environment attempting to accomplish scientific developments trough lengthy and expensive 
R&D cycles while facing insufficient funding. Most companies develop new drugs while not 
generating any revenue, however, the need for funding is critical at each stage of the new drug 
development process. The overall purpose of this study is to describe the challenges in new 
drug development and identify main sources of private and external funding for 
biopharmaceutical companies. The study was conducted as an exploratory research and data 
was collected by interviewing a Finnish biopharmaceutical company.  
To achieve the aim of the study, three streams of literature were reviewed: biotechnology 
industry, new drug development and private and external funding sources in biopharmaceutical 
context. Most empirical findings of the study supported existing literature. This study 
emphasises the importance of funding in new drug development and venture capital and 
alliances with Big Pharma were identified as the main sources of private and external funding 
for biopharmaceutical companies. Key findings were that early-stage drug development can 
attract venture capital and value can be created already at early stages of drug development 
making the company profitable. This thesis contributes to the already existing body of literature 
and offers a practical description of challenges in new drug development and private and 
external funding sources.  
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1 INTRODUCTION 
 
1.1 Background 
Biotechnology has been widely regarded to be of vital importance to the 
economic growth of most national economies, in fact, it has been increasingly 
recognised as " one of the most promising frontier technologies for the coming 
decades" and furthermore,  and it can serve both private and public needs 
(European Commission 2002). Moreover, biotechnology contributes to job 
creation, competitiveness in the EU and promotes economic development 
(European Commission 2007).  
Various researchers and studies (for example, Champion 2001; Baker 2003; 
Arantes- Oliveira 2006; Hine & Kapeleris 2006; Khilji et al 2006; Pisano 2006; 
Vanderbyl & Kobelak 2007) have showed biotech industry is characterised by 
unique elements as the companies operate in high risk environment attempting 
to accomplish scientific developments trough lengthy and expensive R&D 
cycles while facing insufficient funding.   
The concentration of this thesis is on biopharmaceuticals, in other words, in new 
drug development. The new drug development process is long and expensive: 
on average the process takes 14 years and the huge costs associated with 
successful drug development can come to $800 million to $1 billion (Champion 
2001, 110; Hine & Kapeleris 2006; Pisano 2006, 117). Moreover, most 
companies develop new drugs while not generating any revenue due to lack of 
marketable products, which is why only few biotech companies have created 
substantial cash flows or have become profitable (Pisano 2006, 118). However, 
the need for funding, in particular external funding is critical at each stage of the 
new drug development process (Brännback et al 2004, Khilji et al 2006, 533).  
The current trend experienced in the industry is that venture funding from 
investors is becoming 'tranched', particularly in the early rounds of funding, 
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meaning funding is distributed between defined milestones rather than the 
company receiving the money up front; in addition, although there are less 
capital available to companies, they are expected to do more with their 
resources (Ernst and Young 2011). 
Considering the above, the process of attracting private and external funding to 
support new drug development process became of interest. Therefore, this 
study wishes to explore the challenges of new drug development and the role of 
private and external funding in new drug development process in 
biopharmaceutical companies.  
 
1.2 Purpose 
The purpose of this thesis is to study the need of private and external funding in 
new drug development in biopharmaceutical companies. To accomplish this, 
the following research questions were set: 
1. What are the challenges in new drug development process in 
biopharmaceutical context? 
2. What are the main sources of private and external funding in new drug 
development process? 
 
1.3 Structure of the Thesis 
In an attempt to satisfy the two research questions, three streams of literature 
were reviewed: biotechnology industry, new drug development process and 
private and external funding sources in biopharmaceutical context.  From this a 
theoretical understanding was gained to support in the collection of primary 
data. Primary data was collected by a semi-structured interview, in which 
challenges of new drug development process and matters surrounding private 
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and external funding were discussed. The interview was audio-recorded and 
after this transcribed.  
This introductory chapter is followed by Chapter 2 which consists of the 
literature review of overview of biotechnology industry, new drug development 
process and private and external funding sources in biopharmaceutical context. 
Chapter 3 describes the research methods used in this thesis in more detail. 
Chapter 4 presents the findings of the research and Chapter 5 includes the 
conclusions of this thesis.  References can be found listed at the end of this 
thesis.   
  
8 
 
2 LITERATURE REVIEW 
This literature review comprises of three streams of literature: biotechnology 
industry, new drug development process and private and external funding 
sources in biopharmaceutical context. 
Biotechnology "involves use of living organisms or parts of living organism 
through biological processing to develop new products or provide new methods 
of production". Biotechnology industry includes a variety of fields, for example, 
medicine, and agriculture, food processing and environmental maintenance. 
(Hine & Kapeleris 2006, 19). The focus of this thesis is on the development of 
biopharmaceuticals.  The term biopharmaceuticals was initially defined as "a 
class of therapeutic protein produced by modern biotechnological techniques" 
but the developments in the industry within the last 30 years have altered the 
definition to “a protein or nucleic acid based pharmaceutical substance used for 
therapeutic or in vivo diagnostic purposes, which is produced by means other 
than direct extraction from a native (non-engineered) biological source”. (Walsh 
2002, 2).  In other words, the focus of this thesis is on new drug development.  
2.1 Overview of biotechnology industry 
At the centre the biotech industry are the direct participants such as start-ups, 
established companies, investors and customers. These core players are linked 
by institutional arrangements such as markets for capital, products and 
intellectual property and the industry is regulated by strict rules and regulations 
and intellectual property (IP) rights. (Pisano 2006, 115-116.) The structure of 
biotech industry seems to be similar to that of other high technology industries, 
such as IT, however, various researchers and studies (for example, Champion 
2001; Baker 2003; Arantes- Oliveira 2006; Hine & Kapeleris 2006; Khilji et al 
2006; Pisano 2006; Vanderbyl & Kobelak 2007) show the biotech industry is 
characterised by unique elements as they operate in high risk environment 
attempting to accomplish scientific developments trough lengthy and expensive 
R&D cycles while facing insufficient funding.  Moreover, most companies 
operate without generating any revenue, which is why only few biotech 
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companies have created substantial cash flows or have become profitable 
(Pisano 2006, 118). 
At the core of the unique characters of developing biopharmaceuticals is the 
lengthy and expensive R&D cycle: on average the process takes 14 years and 
the huge costs associated with successful drug development can come to $800 
million to $1 billion (Champion 2001, 110; Hine & Kapeleris 2006; Pisano 2006, 
117). In addition, new drug development process includes high risks. The 
conventional concept of product life cycle (PLC) consisting of launch, growth, 
reaching maturity, decline and withdrawal (Howard & Hine 1997 as per Hine & 
Kapeleris 2006, 134) is not appropriate for biotechnology, as in most areas, and 
specifically is the case of developing biopharmaceuticals, there are no tangible 
products which would have reached the market and their progress cannot be 
estimated by turnover cycles of a product. Therefore, it is more appropriate to 
use the concept of research and development (R&D) pipeline to describe the 
development stages from research and discovery to development and 
eventually to the ultimate aim of commercialization. (Hine & Kapeleris 2006, 
133-136). Essentially, research and development (R&D) can be defined as "the 
introduction of and the development of new ideas" (Worthington & Britton 2003, 
143, 497).  The new drug development process detailing the R&D development 
stages are described in detail in the Chapter 2.1.1.     
The study of Nosella et al (2006, 9) noted the structure of the biotech industry 
has developed into more complex environment, but the study identified the 
following business models for biopharmaceutical companies: new biotechnology 
companies, fully integrated companies, manufacturing companies and service 
firms. The new biotechnology firms perform research activities and when 
reaching lead optimisation they license their outputs, for example, new drug 
candidates, to other companies. A fully integrated company has a strong 
pipeline and performs all the activities of the R&D pipeline thus covering all the 
development stages from target identification to commercialization. 
Manufacturing companies concentrate on the later stages of the R&D pipeline 
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by carrying out production and commercialization activities. Service companies 
supply biotech products and sell their research services to other companies.  
In addition to funding being one of the critical success factors for the industry 
(Vanderbyl & Kobelak 2007, 69) successful biotechnology companies also have 
a clear business plan, a strong product development model, a clearly planned 
exit strategy for the investors and an experienced management team (Kulkami 
2005).  According to various researchers (for example, Baker 2003, 287; Brooks 
2003, 26; Hine & Kapeleris 2006, 178) developing multiple products 
concurrently can spread the high risks involved in new drug development. The 
study of Vanderbyl & Kobelak (2007) emphasizes the importance of knowledge 
assets as a critical success factor as the knowledge assets support keeping up 
a continuous pipeline. This is supported by Ireland & Hine (2007, 688) as the 
capability of transforming intellectual capital into a product will have an effect on 
the growth of the company. 
2.1.1 New drug development process in biopharmaceutical context 
The new drug development process in biopharmaceuticals does not differ 
greatly to the one of pharmaceutical industry. However, traditional drug 
discovery uses treatment as the foundation for drug development,   
biopharmaceuticals start by identifying genes connected with a specific disease 
(Hine & Kapeleris 2006, 191). 
The new drug development process in biopharmaceuticals combines scientific 
research and technical development leading to commercialisation of a new 
drug.  Thus, the new drug development process includes three stages: 
research/ discovery, development and commercialization.   
In research/discovery stage, three leads are identified: genes connected with a 
disease (gene identification), target proteins resulting in the disease (target 
identification and validation) and new molecules preventing the disease (lead 
identification) (Champion 2001,110; Hine & Kapeleris 2006, 191).  At this stage, 
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first patent applications are filed. It is necessary to secure patent protection for 
the discovered leads to limit competition (Hine & Kapeleris 2006, 42,50, 118). 
Discovery stage is followed by development stage. The development stage 
involves pre-clinical and clinical testing. In pre-clinical stage the testing is 
performed on animals to test for toxicity. After pre-clinical testing, an 
Investigational New Drug Application (IND) is filed if there is evidence of safety 
and efficacy of the drug. An appropriate regulatory body has to approve the 
application before the product development can continue to the next stage, 
clinical testing. (Champion 2001, 110; Hine & Kapeleris 2006, 38, 180, 191, 
193, Khilji et al 2006, 530.) 
Clinical testing is further divided in to three stages: Phase I, Phase II and Phase 
III. In Phase I the safety, dosage and side effects of the new drug are monitored 
by trialling it on 20-30 clinical trial subjects (healthy individuals). In phase II the 
efficacy and side-effects are assessed on 100-300 clinical trial subjects 
(patients). In phase III the effects of long-term drug use are examined on 1000-
6000 clinical trial subjects (patients) as the new drug is compared to existing 
therapies and drug combinations. (Hine & Kapeleris 2006, 38, 191-193, Khilji et 
al 2006, 530).  The phases occur sequentially and a phase cannot occur if the 
previous phase has not been completed successfully. Of the three phases, 
Phase III takes the longest to complete and is the most expensive to conduct 
(Hine & Kapeleris 2009, 193).  
If the clinical tests have been completed successfully and with favourable 
results, New Drug Application (NDA) is filed.  The appropriate regulatory body 
will then review the application. If the product receives market approval, the 
market launch can begin. (Hine & Kapeleris 2006, 38, 180, 135, 193; Khilji et al 
2006,530.) 
The commercialization stage consists of manufacturing and marketing the drug. 
A company must find ways to economically manufacture the product and build a 
strong market strategy. The commercialization stage normally commences at 
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the late stages of clinical trial. (Champion 2001, 110; Hine & Kapeleris 2006, 38, 
193.) 
As a conclusion, the new drug development process is a lengthy and complex 
process (Champion 2001, 110) consisting of multiple stages. The stages of the 
development process are collated in Figure 1. Furthermore, drug development 
can be seen as emphasising the development of the findings of fundamental 
research (Brännback et al 2004, 32). 
 
Figure 1 New drug development process in biopharmaceutical context 
 
Source: Based on Champion 2001; Hine & Kapeleris 2006; Khilji et al 2006. 
The drug development process is traditionally described linear, however, as 
Hine & Kapeleris (2009, 191, 193) note, there may be overlapping of the 
different stages or they may happen in parallel, for example, after a lead 
candidate has entered the clinical trials, preclinical development may 
sometimes continue and preparations for manufacturing often happens in 
parallel with pre-marketing at the late stages of clinical trials.  
The following chapter will describe the challenges in new drug development 
process in biopharmaceutical context in more detail. 
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2.1.2 Challenges of new drug development process in biopharmaceutical 
context 
New drug development process described in the previous chapter is faced with 
great technical and commercial uncertainty and the level of risks involved at 
each stage of the development process is high. Furthermore, the process is 
long and expensive: on average the process takes 14 years and the huge costs 
associated with successful drug development can come to $800 million to $1 
billion. (Champion 2001, 110;Hine & Kapeleris 2006; Pisano 2006, 117).  
New drug development is shadowed by profound and consistent uncertainty. 
The safety and effectiveness of a drug can only be established through the long 
and highly regulated development process. (Pisano 2006, 119.) The 
development process is effectively a "hugely expensive trial-and-error process" 
(Champion 2001,113). Of 5,000 screened lead candidates, only 250 may reach 
pre-clinical testing. Of those 250 leads, just 5 will enter clinical testing and 
ultimately only one will become an end product, the marketable drug. 
(Champion 2001, 113, Hine & Kapeleris 2006, 126; Pisano 2006, 119.) The 
study of DiMasi (2001, 303) supports this as it shows half of leads will fail at 
phase II. Thus, it is evident that the success rate for a lead candidate passing 
all the stages to commercialization is very low due to the high chance of failure.  
According to Pisano (2006,119) failure can be expected as the most likely result 
of new drug development process. To summarize, the uncertainty involved in 
drug development "translates in to high, long term risks" (Pisano 2006, 119).  
The study of DiMasi shows that efficacy was the main reason for research 
termination of first IND filing with 37.6% closely followed by economic reasons 
with 33.8% and safety problems accounted for 19.6% of the terminations. At the 
later stage developments main reasons for terminations were economic 
reasons (39%) followed by efficacy issues (32%), safety issues being the third 
highest reason (16%) for terminations. (DiMasi 2001, 304). According to CMR 
International (as per Brännback et al 2004, 33) efficacy (22.5%), portfolio 
considerations (21.7 %), clinical safety (20.2%) and toxicology (19.4%) were all 
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on a par with each other as being the main reason for termination in drug 
development process. The importance of economic success in drug 
development process is thus evident.  
On average, the drug development process from discovery to commercialisation 
takes approximately 14 years (Hine & Kapeleris 2006). As described in chapter 
2.1.1, the new drug development process consists of various stages, which 
must be followed to be able to bring a drug to the market. The long lead time to 
production is partly due to the nature of biopharmaceuticals as new drug 
development process is highly regulated by regulatory bodies (Hine & Kapeleris 
2006, 38): Medicines Evaluation Agency (EMEA) in the EU and the US Food 
and Drug Administration (FDA) in the US. The regulation and approval of new 
drugs consist of various stages making the process time-consuming (Hine & 
Kapeleris 2006, 178). The timeframe for the approval process differs 
dramatically between countries; however, approval times for New Molecular 
Entities (NME) are not less than 12 months in any country (Hine & Griffiths 
2004, 142; Hine & Kapeleris 2006, 39). It must be noted, however, that this is 
only one of the activities in the long R&D cycle (Hine & Griffits 2004, 142), but 
most importantly, the ability to eventually commercialize a drug is dependent on 
the approval of a regulatory body (Hine & Kapeleris 2006, 178- 179).  The 
Figure 2 shows the average time different stages take in the new drug 
development process.   
The lengthy development process also denotes a long waiting time from initial 
investment to return on the investment for investors. Thus the length of the new 
drug development process can be an obstacle in attracting funding.  For 
example, venture capitalists (VCs) usually have a timeline of three years for an 
investment, which is a noticeably shorter time than the time it takes to develop a 
drug. In addition to conflicting with the funding, the long R&D cycle also clashes 
with rewarding of risks. (Pisano 2006, 119). 
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Figure 2 The average length of different stages in the new drug 
development process 
 
 
Sources: Adapted from Hine & Kapeleris 2006; Khilji et a 2006. 
 
The biopharmaceutical companies operate "in a climate with minimal resources 
but requiring huge investments to develop technology and secure intellectual 
property (IP) rights" (Vanderbyl & Kobelak 2006, 68). On average, bringing a 
drug to a market costs £500 million (Champion 2001, 110) but the costs can 
rise up to $800 million to $1 billion (Pisano 2006, 117).  There is no great 
difference in the costs of a new drug development between major 
pharmaceutical companies or biopharmaceutical companies (Pisano 2006, 
120). However,  Brännback et al (2004, 33) estimate the cost of a new drug 
development only to be 100-250 million Euros in a right context, of which as 
much as 60% is credited to clinical development. To attract a vast amount of 
funding from investors the company has to make the new drug development 
process into an attractive investment opportunity, although a tangible product 
does not exist. The need for external funding is critical at each stage of the 
development process (Khilji et al 2006, 533) to process through the R&D cycle, 
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however, the need for funding may vary depending on the stage of the 
development.   
While biopharmaceutical companies are developing their drugs, in other words, 
progressing through the R&D cycle, and they are not creating any revenue due 
to lack of marketable products, they are faced with an 'equity gap' as they 
cannot meet the high development costs associated with new drug 
development process.  The gap is a result of "perceptions amongst potential 
investors about the relative balance between the risks associated with a 
potential investment and the potential returns from that investment" (Harding & 
Cowling 2006, 117). This is associated with the reasons why only few biotech 
companies have created substantial cash flows or have become profitable 
(Pisano 2006, 118).  
For a biotech company to be successful, it should aim to develop multiple 
products concurrently (Baker 2003, 287). This is supported by Hine & Kapeleris 
(2006, 178) and Brooks (2003, 26) who note companies with only one product 
in the pipeline are most vulnerable due to the risks involved in the new drug 
development. In addition, Vanderbul & Kobelak (2007, 72) note that a 
differentiated pipeline can help to offset the high failure rate. However, 
Champion (2001, 114) estimates the cost of continuous drug pipeline to be 
between $2billion to $5billion a year in research alone. Most companies do not 
have resources for this (Brooks 2003, 26). As a result, the cost of developing 
multiple products may force a company to choose which development project to 
pursue further. The decision is based on interpreting results from various stages 
of the drug development and the verdict made may vary between individuals 
and companies (Pisano 2006, 122). However, Brooks (2003, 26) also warns of 
having too vast pipeline of developments at early stages as this may not attract 
investors due to concerns over not creating later stage value. In addition, 
Champion (2001, 110, 111) notes that company's position in the process 
determines its profit potential and the margins are small at the early stages of 
development.  
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Champion (2001,113) believes that companies must find means of improving 
the pace and cost effectiveness of the whole drug development process.  This 
is further supported by Baker (2003, 287) according to whom new drugs must 
be brought to the markets in a timely manner to provide funds for further 
discovery and development.  The new drug development process is highly 
regulated by regulatory bodies, which restricts the degree of control the 
biopharmaceutical companies have over the R&D cycle. However, reducing the 
R&D cycle is the only way to provide for greater investment returns before 
patent expiry. (Hine & Griffiths 2004, 142).  
2.2 Private funding sources for biopharmaceutical companies 
Due to the nature and challenges of new drug development process described 
in the Chapter 2.1.1 and Chapter 2.1.2, the need for external funding is critical 
at each stage of the development process (Brännback et al 2004, Khilji et al 
2006, 533). This chapter reviews literature of external funding from private 
sources to investigate how it raises to the challenges of new drug development 
process. 
2.2.1 Overview of funding strategies of new drug development process 
Biopharmaceutical companies' needs for financial resources can be 
characteristics as follows: despite having high development costs, they are not 
generating any revenue, the demand for finance is taken in steps instead of the 
demand developing gradually and high growth requires large amounts of capital 
(Gabrielsson 200, 3). Traditional sources of finance are usually unsuitable for 
biopharmaceutical companies, especially debt financing is considered 
unsuitable at the early stages of drug development.  For example, banks are 
unlikely to fund early stages of drug development due to the high risks involved 
as the risk/return ratio is not favourable. (Whitehead 2003, 245). Thus venture 
capital (VC) funding is an important factor in the industry (Hine & Kapeleris 
2006, 78).   
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The funding of drug development process can come from several sources: 
primary funding from founders, family and friends, pre-seed and seed funding 
from business angels and government, venture capital (VC) funding and Initial 
Public Offering (IPO).  Each of these sources has distinct characteristics, 
different criteria, motives and level of involvement in drug development process. 
(Hine & Kapeleris 2006, 49, 54; Gabrielsson et al 2004). The informal venture 
market of business angels and friends and family is considered to be 
extensively larger than the formal venture market of banks, financial institutions 
and other institutions (Hine & Kapeleris 2006, 78). In addition, alliances with Big 
Pharma are a common way of organising funding in the industry. Figure 3 
shows the typical equity and investment funding for biotech companies. The 
different sources of private and external funding will be discussed in more detail 
in chapter 2.2.2. 
 
Figure 3 Source of equity investment funding for biotech firms 
 
Source: Based on Hine & Kapeleris 2006. 
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Biopharmaceutical company often receives pre-seed and seed funding from the 
government for example, in forms of specialised programs, grants and fiscal 
benefits and as the company grows finance is often sought from private 
sources. (Arantes-Oliviera 2006,68; Hine & Kapeleris 2006, 51). As this thesis 
concentrates on private sources of funding, the option of gaining funding from 
public sources, for example, government grants, is outside of the scope of this 
thesis and thus is not discussed further.  
The major types of venture capital (fixed capital, working capital and growth 
capital) are not appropriate criteria for funding high technology ventures, which 
is why stage of funding and furthermore amount of funding with stage of 
development are often used as defining criteria  (Hine & Kapeleris 2006, 49). 
Internationally , most funding deals  are done at discovery phase  at 44 per 
cent, 16 per cent are done pre-clinical stage, followed by 10 percent of funding 
deals at phase I and phase II. Further 6 percent of the funding deals are done in 
phase III, with 5 percent being done at registration and 19 percent after launch. 
(Allant 2004, as per Hine & Kapeleris 2006, 49). Figure 4 summarises the 
funding deals at each development stage.   
Figure 4 Funding deals at each development stage 
 
 
Source: Based on Allant 2004 as per Hine & Kapeleris 2006. 
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According to Khilji et al (2006, 531) most funds available are concentrated on 
R&D activities during pre-discovery stages, nevertheless, the lack of a tangible 
product weakens the investment opportunity for private investors. 
Consequently, when a tangible product is available, the investment opportunity 
becomes more attractive to the venture capitalists, business angels and 
corporate venture funds. In situations, where the availability of high risk and 
long-term funding solution is scarce, a biopharmaceutical company may have to 
opt to short-term revenue activities while simultaneously or in place of going 
through long and expensive drug development process (Arantes-Oliviera 
2006,65).  
2.2.2 Sources of private and external funding in new drug development 
process 
2.2.2.1 Founders, Family and Friends 
Primary funding sources consist of private individuals: the founder, family and 
friends. Most often cash to build up facilities is provided in exchange of equity in 
the firm.  These sources of investment are most often used at the discovery 
stage. However, the expensive R&D related to drug development, high burn 
rates and the need for facilities such as scientific expertise and equipment lead 
to a remarkable equity gap in funding which cannot be covered by founders, 
family and friends. (Hine & Kapeleris 2006, 52.)  
2.2.2.2 Business Angels 
Private business angels may provide further seed funding to the company. 
Business angels are wealthy private investors. Most often the investment savvy 
business angels invest only 5 to 15 per cent of their possible investment 
portfolio into high- risky ventures. This suggests business angels do not invest 
what they can't afford to lose and, in addition, the amount invested in high-risk 
ventures is proportional to the health of their investments on the wide markets. 
(Whitehead 2003, 242.) In particular, early-stage companies are usually 
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dependant on the business angels to provide funding at the start in order to 
attract more wide investment base in the future (Vanderbyl & Kobelak 2007, 
72).   
Due to the complex nature of biotechnology industries, business angels are less 
common in comparison to other industries. The business angels need to have 
the scientific knowledge to understand the investment, enough capital to afford 
the high costs of the investment, patience due to the long R&D cycle and 
tendency to endure the high risks involved with the investment. (Whitehead 
2003, 242.) Often business angels invest in companies in the same sector (Hine 
& Kapeleris 2006, 52) in which they have experience and feel confident in. In 
addition to funding, business angels provide management expertise to the 
company they have invested in (Hine & Kapeleris 2006, 52).  
Furthermore, business angels' contacts can prove to be valuable to a biotech 
company as they often lead to syndicates of investors. Syndicate of investors is 
a group of like-minded private investors. The syndicate spreads the investors' 
individual risks as they are investing smaller individual amounts which 
collectively add up to the amount of funding sought. In addition, business angels 
invest to a wider portfolio through a syndicate spreading the risks more. Before 
investing in a company, a due diligence is conducted to assess the investment 
opportunity in the company. (Whitehead 2003, 243.) Due diligence is defined by 
the "process of evaluation a prospective business decision by investigating 
relevant financial, legal, and other important information about the other party" 
(Osborne & Petheram 2010, 109).  Investing through a syndicate includes 
advantages for both the business angels and the company: investors spread 
their risk and gain better valuation based on an effective group bargaining 
power and the company attracts the investment and saves time and money by 
attracting investment from many simultaneously (Whitehead 2003, 243).  
The accessibility to business angels is dependent on the maturity of region's 
biotech industry. In major biotech industries there is a large pool of angels 
compared to the smaller pools of maturing and immature biotech hubs. In less 
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mature biotech industries the importance of informal investors, such as 
business angels, is high (Hine & Kapeleris 2006, 52). 
Business angels make investments in the areas in which other investors, such 
as institutional investors, are reluctant to invest i.e. in risky investment 
opportunities and thus filling the equity gap. Thus funding provided by business 
angels is most often needed at the early stages of drug development process, 
especially in the pre- clinical stage when probability of high growth and returns 
are low to medium and the risks are high. (Hine & Kapeleris 2006, 38, 52.) Due 
to the informal nature of angel funding, the amounts of investments are difficult 
to establish (Hine & Kapeleris 2006, 52), however, the investments most often 
are below £1 million (Whitehead 2003, 244). Table 1 broadly describes the 
characteristics of business angels. 
Table 1: Characteristics of business angels 
Business Angels 
Below £1 million 
Very dependent on the individual investors 
Have a personal interest in the business 
Forgiving (i.e. may invest although management team is not complete) 
Very limited funds - follow-on funding is unlikely 
 
Source: Based on Whitehead 2003. 
 
2.2.2.3 Venture Capitalists 
Venture capital is defined as "being investment in unquoted firms usually 
associated with high risk and in its original sense primarily directed towards 
young, often technology based firms with high growth potential" (Christensen & 
Christensen 2003, 156). Venture capitalists (VCs) are professional fund 
managers, who manage funds for other investors, such as banks and pension 
funds. (Whitehead 2003, 243; Hine & Kapeleris 2006, 53). However, there are 
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differences in venture capital definitions in official statistics: in Europe later 
stage equity financing is included in venture capital, but in the US it is not 
(Christensen & Christensen 2003, 156). Venture capital, also known as risk 
capital, is usually in the form of equity (Hine & Kapeleris 2006, 53), however, it 
could also be in forms which are related to the profits of the company, for 
example, converting it to shares or rendering a return (Christensen & 
Christensen 2003, 156). VCs rarely fund early-stage drug development due to 
the high risks involved and generally back up companies in the later stages of 
the development. (Hine & Kapeleris 2006, 50, 53). Venture funding events are 
usually called rounds.  
The VCs' motive is to make a significant return on their investment, which 
translates into a healthy profit and as a result, deals below £1 million are usually 
regarded as economically unviable (Whitehead 2003, 244).  The VCs thus 
make investments at the stages of clinical trials, when the risks are lower than 
in the previous stages, and the probability of high growth and returns are higher 
(Hine & Kapeleris 2006,38, 50) and the need for funding is greater. However, 
due to the vast amount of money required to bring a drug in to the market, not 
even the largest VC funds can provide all the financing as they have to spread 
their risks (Pisano 2006, 119). Moreover, VCs usually expect the investment to 
provide a return within three to ten year-period (Hine & Kapeleris 2006, 53; 
Pisano 2006, 119). 
Venture capital investment decisions take usually from 2 to 12 months (Hine & 
Kapeleris 2006, 53).  Similarly to the syndicate of private investors, the VCs 
conduct a thorough due diligence to assess the investment opportunity in the 
company, stressing issues such as science base, business plan, company 
strategy and management team (Whitehead 2003, 244, Brooks 2003, 23). In 
addition, they assess previous development success and critical mass of the 
company (Brooks 2003, 24). Long negotiations in relation to equity and 
milestones usually take place prior to investment decision (Hine & Kapeleris 
2006, 53).  
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In addition to funding, VCs bring a network of experienced contacts, such as 
accounting and law firms, and professional managers to help the company. 
Furthermore, VCs themselves bring reputation that has effect on the profile and 
credibility of the company. (Davila et al 2003, 691.) The VCs usually insist on a 
significant role in the operations of the company, for example, a board position 
or involvement on day-to-day operational management. (Christensen & 
Christensen 2006, 156; Whitehead 2003, 244; Hine & Kapeleris 2006, 53).  The 
position of a VC in the company depends on the degree of development of the 
company (Hine & Kapeleris 2006, 53). 
Usually the VCs invest in specific sectors (Whitehead 2003, 244; Hine & 
Kapeleris 2006,53), however, most often VCs spread their risk by having a 
portfolio approach, in other words, mixing their investments, or syndicating 
investments with other investors (Hine & Kapeleris 2006, 53).  
VC funding events are not only a source of funding; it is also an positive 
indication of the quality of the development, bringing more credibility and thus 
decrease the uncertainty of the development's possibly success (Davila et al 
2003, 691, 692, 706). This is further supported by Christensen & Christensen 
(2003, 156) who state that it appears the development of companies is 
positively affected by venture capital. Furthermore, investors often see 
themselves vital for success of a company as they can provide insights of the 
company the management cannot produce themselves (Fischer & Reuber 
2003, 53). 
Historically, VC investments appear to be dependent on the maturity of region's 
biotech industry; VC investments are more successful for example in the US, 
where the stock market is more mature and the supporting conditions for VC 
investments are more favourable alongside with conditions supporting 
entrepreneurship (Giesecke 2000; Arantes-Oliviera 2006, 65). Arantes- Oliviera 
also notes the problem of investors lacking specialised knowledge of the 
biotech industry (2006, 68). Table 2 broadly describes the characteristics of 
venture capitalists.  
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Table 2: Characteristics of venture capitalists 
Venture Capitalists 
Above £1 million 
Very sector- specific 
Professionalism throughout the business required 
Strong management required 
Strong IP rights expected 
Board position 
Large equity stake 
Experts in getting most out of a deal 
 
Source: Based on Whitehead 2003. 
 
2.2.2.4 Initial Public Offering 
International Public Offering (IPO) is where the company is listed publicly on a 
stock exchange (Hine & Kapeleris 2006, 54). IPO's function is to raise capital for 
the company (Deeds et al 1997, 38). Moving to IPO places major financial and 
managerial demands on the company such as strict reporting and accounting 
processes and the cost of IPO is significant. Usually IPO is one of the last 
sources of funding and is considered at the late stages of clinical trials. (Hine & 
Kapeleris 2006, 38, 54). An obvious correlation exists between the amount of 
money invested in a company prior to IPO history and its value at IPO (Brooks 
2003, 278). Historically biotechnology has had major success in relation to 
public offerings in 1999 and 2000, however, there were major failures in 2001 
and 2002 with investor confidence increasing from 2004 onwards. (Hine & 
Kapeleris 2006, 54). 
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2.2.2.5 Alliances with Big Pharma 
As noted in chapter 2.2.1 a strategic alliance with a large pharmaceutical 
company, Big Pharma, is a common way of gaining funding in the biotech 
industry. Most often a strategic alliance is required to launch the product to the 
market (Hine & Kapeleris 2006, 19). Strategic alliances are based on 
monetizing intellectual property (Pisano 2006, 117) by licensing out patented 
intellectual property (IP) or by forming collaboration, partnerships and joint 
ventures. Licensing means the transfer of IP either on exclusive or non-
exclusive basis. Licensing IP can occur at any stage of the development 
process, where as collaboration is generally formed at an early stage and a joint 
venture is established at a later stage. (Hine & Kapeleris 2006, 72-73.) 
Strategic alliance can benefit a biopharmaceutical company by securing funding 
and resources (Hine & Kapeleris 2006, 23) but also by broadening its 
capabilities (Champion 2001,113).  The structure of the alliance and the position 
of a biopharmaceutical company in a strategic alliance depends on the stage of 
the development and in-house possibilities of the company, for example, a 
company in early stages of development can give away ownership of any 
targets identified keeping the rights to a royalty interest, but as the company 
moves down the value chain they are able to maintain more control and an 
ownership stake over the products becoming more 50-50 alliances. (Champion 
2001, 113; Hine & Kapeleris 2006, 138).  
From the point of view of Big Pharma, alliances with biopharmaceutical 
companies effectively mean outsourcing their R&D and most often it is in those 
areas where it is missing expertise (Pisano 2006, 117, 120), in addition, they 
are thus spreading their own risk. 
However, as the research of Khilji et al (2006, 535) found out, forming strategic 
alliances can be a complicated process due to the patented information and 
scientific discoveries.  However, practically every new biopharmaceutical 
company has to form at least one alliance with Big Pharma, while most of the 
companies will have to form numerous alliances (Pisano 2006, 117). 
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Furthermore, an investment from or a collaboration with a large pharmaceutical 
company not only contributes to the growth of a company but it also brings 
credibility to the biopharmaceutical company. In countries where large 
pharmaceutical companies do not exist, large foreign companies should be 
attracted to that country to ensure investment in biopharmaceutical companies. 
(Arentes-Oliviera 2006, 67).  
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3 RESEARCH METHODOLOGY 
In this chapter, the research design will be explained, data collection process 
will be described after which the limitations to this study are discussed. This is 
followed by a brief introductory of the researched company. 
3.1 Research design 
An exploratory study gives means to find out "what is happening; to seek new 
insights; to ask questions and to assess phenomena in a new light" (Robson 
2002, 59). By using the method of exploratory research this study can identify 
the main challenges in new drug development and find out how the private 
external sources of funding raises to the challenges while trying to seek new 
insights in to the relationship between these two issues. The three primary 
means of conducting exploratory research are searching literature, interviewing 
experts in the research field and/or conducting focus group interviews 
(Saunders et al 2007, 133). This thesis used the first two first techniques. 
Previous literature concerning biotechnology industry, new drug development 
and private and external funding sources in biopharmaceutical context were 
studied in detail; a combination of journal articles, books, websites of 
biotechnology companies and organisations related to the industry.  
Due to the sensitive nature of the topic of the thesis, quantitative data was 
difficult to find due to this information not being public and using only qualitative 
techniques was considered to be adequate in trying to satisfy the research 
questions, thus an interview was chosen for this purpose. Also, as it was 
important to understand the reasons to my research participant's opinions, it 
was necessary to conduct a qualitative interview (Saunders et al 2007, 315). 
The interview was the main and only method for data collection. The interview 
was based on list of themes and questions (Saunders et al 2007, 312) while at 
the same enabling flexibility on clarifying given answers further and presenting 
additional questions. The conversation was kept within the chosen themes and 
questions to ensure the validity of the data. The chosen themes and questions 
included the company's history, the type of products/ services the company 
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offers, characteristics of the pipeline, internal capacities, market factors and 
innovative performance of the company. The semi- structured interview with the 
company representative lasted approximately 1 hour, and was audio-recorded 
and after this transcribed (Saunders et al 2007, 475).  The transcription was 
done manually. Categories were developed based on the themes in the 
interview and units of data were attached to relevant categories (Sanders et al 
2007, 480).  
In choosing the interviewee, importance was placed on the direct experience of 
the interviewee to obtain information relevant to this study. The company 
representative, the interviewee, chosen for the interview was the CEO of the 
company due to the CEO's vast and direct experience in development projects 
from discovery to commercial success as part of the current company and also 
as part of previous companies having been involved in drug development for 
over a decade. 
It is recognised that there are various limitations to this study. The research 
would have greatly benefited from having multiple cases to assist with 
generating a wider understanding of the matters researched. This was the 
intention of the researcher; however, due to the sensitive nature of the research 
topic, companies were not willing to discuss matters relating to their private and 
external funding sources and thus they could not be included in the research.  
Therefore, this research has no basis for scientific generalisation. In addition, 
some limitations are related to the availability of data. Some of the data on 
private and external sources of funding is not public and thus could not be 
analysed. Revealing this information was left up to the representative of the 
company, however, due to non-disclosure agreements between the company 
and the co-operative partners some of the information may not have been 
revealed. The limitations described may have had an impact of the outcome of 
research.  
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3.2 Company profile 
The researched company operates in Finland and was founded after 2004, 
which is considered to be a turning point from financial aspects in biotech 
industry due to the market conditions. The company is a privately owned and 
backed by venture capital. The company concentrates on discovery, preclinical 
research and early development of novel therapeutics. The company's pipeline 
is based on internal research and inventions.  Currently, the company has five 
products in the pipeline. The company has successfully received both public 
and private external funding for their drug developments and the amount 
received has been approximately 5 million Euros. They have received around 
half of that from Finnish public sources and half from venture capitalists. R&D 
spending since founding the company has been approximately 3 million Euros. 
They are currently partnered with a large pharmaceutical company. The 
company employs less than 10 people. The company has applied intellectual 
property rights for three of their molecules.  
4 FINDINGS 
In this chapter the data gained from the interview conducted with the company 
representative will be presented. 
New drug development process described in chapter 2.1.1 is faced with great 
technical and commercial uncertainty and the level of risks involved at each 
stage of the development process is high. Furthermore, the process is long and 
expensive: on average the process takes 14 years and the huge costs 
associated with successful drug development can come to $800 million to $1 
billion. (Champion 2001, 110; Hine & Kapeleris 2006; Pisano 2006, 117). Due to 
the nature and challenges of new drug development process, the need for 
external funding is critical at each stage of the development process 
(Brännback et al 2004, Khilji et al 2006, 533).  The company stated funding is 
one of the most important factors contributing to the success of the company. 
The company had received a VC funding round in 2008, which meant they have 
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not had an urgent need to actively seek for new financing deals; however, a 
considerable amount of time is still currently being spent on planning funding 
strategies: "If you miss the window of opportunity due to funding, you can ruin 
the future of the company". Therefore, funding is of most importance to the 
success of a biopharmaceutical company. Figure 5 presents the company's 
funding milestones in a chronological order.  
Figure 5 Timeline of company's funding milestones 
 
The company named access to capital and access to international markets as 
the most significant barriers to their R&D activities. However, as the company 
has been successful in attracting both public and private funding, the 
interviewee did state they do not feel access to capital has been a major issue 
for them. However, as they are not in dealings with any regulatory issues and 
they have always had highly skilled people within the company, they have not 
experienced challenges with access to skilled human resources, although this is 
generally a problem in Finland.  
The earlier a failing compound as development target is terminated the more 
resources can be saved by a company. The leading reason for terminations of 
new drug developments is economical reasons, both at the early-stage 
developments and but also increasingly at later stage developments (DiMasi 
2001, 304; CRM International as per Brännback et al 2004, 33.) which would 
indicate economical and competitive advantages of a new drug are not 
considered carefully enough at the discovery stage, although companies should 
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focus on the these advantages from early on (Schmid E. & Smith D 2005). 
However, the interviewee confirmed the commercial and competitive 
advantages are taken into consideration before a development process has 
even started as it is crucial for them to be aware of the competitive clinical 
advantages of a compound when it is compared to rivalling compounds in the 
future as they cannot waste their resources on a compound which does not 
have commercial or competitive advantages.  
Various researches have suggested that in order for a biopharmaceutical 
company to be successful it should aim to develop multiple products 
simultaneously as companies with only one product in the pipeline are most 
vulnerable due to the risks involved in the new drug development process. 
(Baker 2003, 287; Brooks 2003, 26; Hine & Kapeleris 2006, 178; Vanderbul & 
Kobelak 2007, 72). The interviewee did support this view: "I do agree that 
having only one product in the pipeline is too risky and it is a no-go for the 
investors, however, at the same time, it is not good to have too of a diverse 
pipeline either, you will only lose you focus and you will definitely run out of 
resources- it is all about getting the balance right." The interviewee also stated 
they seek external consultancy opinions on managing their pipeline with the 
resources they have to maintain a realistic pipeline.  
Although the view of finding the correct balance within the pipeline had also 
been represented in the literature review, Brooks (2003, 26) warns of having a 
too vast pipeline of developments at early stages, not because of running out of 
resources, but because this may not attract investors due to concerns over not 
creating later stage value. The interviewee took a contrary view to the matter: 
"This is a very traditional way of thinking- nothing is worth of any value until you 
have the actual product in your hand- and our company wants to question this 
way of thinking." The company has no intention of taking their compounds 
themselves further than the end of non-clinical stages. In fact, the company 
believes this will be a better solution for them profitability -wise as the 
interviewee explains: "Of course I understand it means the absolute value of the 
drug is not 600 to 800 million Euros, however, I do believe we get a better 
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return on our investment by taking the compounds only to pre-clinical stages 
when considering the resources spent on it versus the return we will receive, 
rather than if we would invest a further 20-40 million Euros ourselves and taking 
the compound to phases I and II, when the return on investments for us is 
smaller. This outlook is somewhat contrary to the views of Champion (2001, 
110) who notes that notes that company's position in the process determines its 
profit potential, however, the margins are small at the early stages of 
development. 
The company has currently five products in the pipeline, which for them is the 
right balance at the moment. Baker (2003, 287) states a biotech company has 
to be able to deliver repeated innovation to maintain competitive advantage "as 
continuous pipeline is the lifeline of the company". The study of Vanderbyl & 
Kobelak (2007) emphasizes the importance of knowledge assets as a critical 
success factor as the knowledge assets support keeping up a continuous 
pipeline. The interviewee did not mention funding as a reason for having a full 
pipeline, instead the interviewee stated the sole reason for the company to be 
constantly able to innovate and thus being able to keep their pipeline full is their 
network: "We have fully committed experts working for us and we are constantly 
innovating or someone has heard of us through our academic or corporate 
network and that way we become involved in new development processes".  
Venture capitalists rarely fund early-stage product development due to the high 
risks involved and generally back companies up in the later stages of the 
development: the investments are usually done during clinical trials when the 
risks are lower than in the previous stages, and the probability of high growth 
and returns are higher (Hine & Kapeleris 2006, 38, 50, 53). However, the 
researched company only concentrates on the discovery, preclinical research 
and early development of novel therapeutics and has been successful in 
gaining venture capital already at very early stages of drug development. 
Successful biotech companies have been deemed to have a clear business 
plan, a strong product development model, a clearly planned exit strategy for 
the investors and an experienced management team (Kulkami 2005). VCs 
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conduct a thorough due diligence to assess the investment opportunity in the 
company, stressing issues such as science base, business plan, company 
strategy and management team (Whitehead 2003, 244, Brooks 2003, 23). In 
addition, they assess previous development success and critical mass of the 
company (Brooks 2003, 24). The CEO strongly believes the reason for the 
company having attracted funding from venture capitalists lies with the team 
and their experience: "We had experience of the industry and its participants 
through previous businesses before we founded the company and we also 
spent a considerable amount of time on building a credible, diversified and 
experienced team before we even approached the investors, so the risk for the 
investors to invest in us was smaller.  If your team is not credible, you will not 
attract funding from any source... The people are very important criteria for the 
investors. I would say that you can make a project which is based on an 
average science a success with the right people and vice versa; a brilliant 
science project will not be a success without the right people." Thus, it can be 
concluded that venture capitalist place a great deal of importance on credible 
and excellent team requiring professionalism throughout the business and 
strong management. However, the interviewee stated that IP rights do not play 
a significant role in the investment decisions: "Of course you must have or have 
applied for IP rights for the compound as this protects your product, however, 
investors do not have the understanding or the willingness to start valuing IP 
rights at the time of making the deal, it is know-how that is valued more." 
Venture capital in Finland is scarce (Invest in Finland 2011, 6) and historically, 
VC investments appear to be dependent on the maturity of region's biotech 
industry; VC investments are more successful for example in the US, where the 
stock market is more mature and the supporting conditions for VC investments 
are more favourable alongside with conditions supporting entrepreneurship 
(Giesecke 2000; Arantes-Oliviera 2006, 65). Arantes- Oliviera also notes the 
problem of investors lacking specialised knowledge of the biotech industry 
(2006, 68). The interviewee agreed that venture capital in Finland is immature 
and the main challenge being there are not enough participants in the Finnish 
market. However, the interviewee noted a change in investors' knowledge and 
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understanding of the requirements in the industry: "... this is an area where 
there has been a significant increase within the last ten years." In Finland there 
is no room for "me-too" type of products as the interviewee describes: "... the 
products must be unique in reality, although at the same time they cannot be 
too complex to understand and they have to be applicable to a considerable 
population". Internationally, the challenge in VC markets is to attract the 
investment as many venture capitalists are not ready to invest due to high risks 
involved and huge disappointments experienced previously which is why drug 
development is usually excluded of VC investments.   Table 3 summarises the 
findings on venture capital. 
Table 3 Findings on venture capital 
Venture Capitalists 
Very sector- specific 
New drugs have to be unique but not 
too complex to understand. Investors' 
understanding of the industry has 
increased. 
Professionalism throughout the business and 
requirement for strong management 
The importance of excellent and 
skilled team (experts) is emphasised. 
Strong IP rights required 
IP rights must exist, but investors 
place more importance on know-how. 
Availability dependant on the maturity of 
region's biotech industry 
VC market in Finland is immature; 
not enough players, only few active 
participants. 
 
A strategic alliance with a large pharmaceutical company, Big Pharma, is a 
common way of gaining funding in the biotech industry. Strategic alliance can 
benefit a biopharmaceutical company by securing funding and resources (Hine 
& Kapeleris 2006, 23) but also by broadening its capabilities (Champion 2001, 
113).  In countries where large pharmaceutical companies do not exist, large 
foreign companies should be attracted to that country to ensure investment in 
biopharmaceutical companies (Arentes-Oliviera 2006, 67). The view that large 
pharmaceutical companies provide funding, resources and broadens the 
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company's capabilities was supported by the interviewee who stated the partner 
of choice must complement the company's own skills and know-how and thus 
have capabilities, experience and know-how in clinical development, regulatory 
affairs and commercialisation of a drug. The importance of international 
presence of a large pharmaceutical company was emphasised.   
Practically every new biopharmaceutical company has to form at least one 
alliance with Big Pharma, while most of the companies will have to form 
numerous alliances (Pisano 2006, 117). The alliances with Big Pharma are very 
important for small biopharmaceutical companies at early stage development, 
which is portrayed by the fact that the interviewee named "increasing the value 
of their company to attract a large international pharmaceutical company to an 
alliance" to take their non-partnered compounds to clinical stages as their main 
strategic goal.  
An investment from or a collaboration with a large pharmaceutical company not 
only contributes to the growth of a company but it also brings credibility to the 
biopharmaceutical company (Arentes-Oliviera 2006, 67). The interviewee fully 
agreed: "We have been able to build credibility as a company in the market and 
the best reference of the credibility is the fact we have been able partner one of 
our very high-risk developments and the development is still going strong." 
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5 CONCLUSIONS 
The research aim of this thesis was to describe the main challenges in new 
drug development process and identify the main private and external funding 
sources of new drug development process. For the most part, the empirical 
findings of this study seemed to support existing literature. However, some 
findings open possibilities for future research.  
The significance of this thesis is mainly managerial as it puts forward more 
practical description of challenges in new drug development process and main 
funding sources of new drug development. From theoretical point of view, this 
thesis adds to the already existing body of literature on new product 
development and funding.   
The concentration of this thesis was on the development of biopharmaceuticals, 
in other words, in new drug development. This thesis consisted of literature 
review starting with an overview of biotech industry describing the new drug 
development process and related challenges, identifying the private and 
external funding sources for biopharmaceutical companies in Chapter 2, 
followed by detailed explanation of the research methods used in Chapter 3. 
Findings of the research were presented in Chapter 4 and this Chapter will 
conclude this thesis. Recommendations for future research and list of 
references can be found at the end of this thesis.  
This study acknowledged that biotech industry is characterised by unique 
elements as the companies operate in high risk environment attempting to 
accomplish scientific developments trough lengthy and expensive R&D cycles 
while facing insufficient funding. Moreover, most companies operate without 
generating any revenue, which is why only few biotech companies have created 
substantial cash flows or have become profitable. (Champion 2001; Baker 
2003; Arantes- Oliveira 2006; Hine & Kapeleris 2006; Khilji et al 2006; Pisano 
2006, Vanderbyl & Kobelak 2007). This study accepted that the traditional 
concept of product life cycle (PLC) is not appropriate for biotech companies and 
concept of research & development (R&D) pipeline describing the development 
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stages from research and discovery to development and eventually to 
commercialization (Hine & Kapeleris 2006, 133-136) would be more 
appropriate. The lengthy and expensive R&D cycle is a unique character of the 
industry affecting the whole drug development process and on average the 
process takes 14 years and the huge costs associated with successful drug 
development can come to $800 million to $1 billion (Champion 2001, 110; Hine 
& Kapeleris 2006; Pisano 2006, 117).  The need for external funding is critical at 
each stage of the drug development process (Brännback et al 2004, Khilji et al 
2006, 533). This study showed that funding is of most importance to a 
development process and planning funding strategies is one of the main 
activities in biopharmaceutical companies. In addition to funding, previous 
literature identified that successful biotechnology companies also have a clear 
business plan, a strong product development model, a clearly planned exit 
strategy for the investors and an experienced management team (Kulkami 
2005). The study of Vanderbyl & Kobelak (2007) emphasizes the importance of 
knowledge assets as a critical success factor as the knowledge assets support 
keeping up a continuous pipeline. In line with Vanderbyl & Kobelak, this study 
highlighted the importance of academic and corporate networks to be able to 
keep innovating and thus being able to maintain a full pipeline. This finding is 
important, as the ability to deliver repeated innovation, in other words having a 
continuous pipeline, is the "life line of a company" and assists in maintaining 
competitive advantage (Baker 2003, 287).  
This study described the stages of the lengthy and complex new drug 
development process in detail from research and discovery to development and 
to commercialization. The process starts by gene identification, target 
identification and validation and lead identification after which first patent 
applications are filed. The development stage includes pre-clinical and clinical 
testing. After pre-clinical testing on animal models, an Investigational New Drug 
Application (IND) is filed if there is evidence of safety and efficacy of the drug. 
Clinical testing is divided into three stages: Phase I, Phase II and Phase III. The 
phases occur sequentially and a phase cannot occur if the previous phase has 
not been completed successfully. If the clinical tests have been completed 
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successfully and with favourable results, New Drug Application (NDA) is filed.  
The appropriate regulatory body will then review the application. If the product 
receives market approval, the market launch can begin. The commercialization 
stage consists of manufacturing and marketing the drug. (Champion 2001; Hine 
& Kapeleris 2006; Khilji et al 2006). 
New drug development is shadowed by profound and consistent uncertainty as 
the safety and effectiveness of a drug can only be established through the long 
and highly regulated development process and failure can be expected as the 
most likely result of the development process (Pisano 2006, 119.) Main reason 
for research termination at early and later stage developments are economic 
reasons (DiMasi 2001, 304) which highlights the importance of economic 
success in drug development. This study showed that economical and 
competitive advantages of a new drug are considered by companies before the 
development process even starts.  
Various researchers have suggested that in order for a biopharmaceutical 
company to be successful it should aim to develop multiple products 
simultaneously as companies with only one product in the pipeline are most 
vulnerable due to the risks involved in the new drug development process. 
(Baker 2003, 287; Brooks 2003, 26; Hine & Kapeleris 2006, 178; Vanderbul & 
Kobelak 2007, 72). The study found that having only one product is too risky, 
however, pipeline should not be too diverse either and the balance between 
having too many and not having enough developments is of most importance.  
Although the view of finding the correct balance within the pipeline had also 
been represented in the literature review, Brooks (2003,26) warns about having 
a too vast pipeline of developments at early stage, not because of running out 
of resources, but because this may not attract investors due to concerns over 
not creating late stage value. However, this study took a contrary view to the 
matter. Although a drug's absolute value cannot be 600 to 800 million Euros at 
the early stages, the study drew attention to the fact that value can already be 
created at the non-clinical stages through this making a company profitable as 
this will offer better returns on investment for the company than when 
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developing the drug further themselves. The view of "nothing is worth any value 
until you have a product in your hand" was deemed to be slightly old-fashioned, 
but traditional, approach to drug development. 
The study understood the traditional funding sources are usually unsuitable for 
biopharmaceutical companies due to the nature of drug development. The drug 
development process shape the biopharmaceutical companies' funding needs 
and three unique characteristics could be identified: despite having high 
development costs, they are not generating any revenue, the demand for 
finance is taken in steps instead of the demand developing gradually and high 
growth requires large amounts of capital (Gabrielsson 200, 3). 
To attract funding biopharmaceutical companies have to become an attractive 
investment opportunity for the investors. However, the lack of a tangible product 
weakens the investment opportunity for private investors and consequently, 
when a tangible product is available, the investment opportunity becomes more 
attractive (Khilji et al 2006, 531). 
The funding of drug development process can come from several sources: 
primary funding from founders, family and friends, pre-seed and seed funding 
from business angels and government, venture capitalist funding and Initial 
Public Offering (IPO).  Each of these sources has distinct characteristics, 
different criteria, motives and level of involvement in drug development process. 
(Hine & Kapeleris 2006, 49, 54. Gabrielsson et al 2004). Alliances with Big 
Pharma are also a common way of organising funding in the industry.  This 
study found that venture capital funding and alliances with Big Pharma are the 
most important private and external funding sources for a biopharmaceutical 
company.  
Venture capitalists rarely fund early-stage product development due to the high 
risks involved and generally back companies up in the later stages of the 
development (Hine & Kapeleris 2006, 38, 50, 53) however this study showed 
that companies which concentrate only at the early stages of the development 
process are able to attract funding from VCs. VCs conduct a thorough due 
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diligence to assess the investment opportunity in the company, stressing issues 
such as science base, business plan, company strategy and management team 
(Whitehead 2003, 244, Brooks 2003, 23). In addition, they assess previous 
development success and critical mass of the company (Brooks 2003, 24). This 
study highlighted the importance of a credible, diversified and experienced team 
as criteria to attract funding from VCs. The study also showed that although IP 
rights must exist, investors place more value on know-how. It was identified that 
although venture capital market in Finland is immature, investors' knowledge 
and understanding of the industry has improved within the last 10 years.  
This study confirmed what was describes in previous literature on alliances with 
Big Pharma: they are a common way of organising funding for small 
biopharmaceutical companies and in addition to securing funding and 
resources, it also benefits a biopharmaceutical company by broadening its 
capabilities (Champion 2001,113; Hine & Kapeleris 2006, 23). It was identified 
that the partner of choice must complement the biopharmaceutical company's 
own skills and know-how and thus have capabilities, experience and know-how 
in clinical development, regulatory affairs and commercialisation of a drug. The 
importance of international presence of a large pharmaceutical company was 
emphasised.  An alliance with Big Pharma was shown to be one of main 
strategic goals of small biopharmaceutical companies and should an alliance 
take place, it will bring credibility in the market to the biopharmaceutical 
company. 
While acknowledging the limitation of this thesis, this study was restricted to 
Finland and thus it would be interesting to compare private and external funding 
in various countries as depending on the maturity of countries' biotech industry 
the findings may vary. In addition, if this research was to be continued, it would 
be interesting to look further into the findings of this study which were in 
contrast with previous literature; creating value already at the non-clinical 
stages of the development process and through this making a drug 
development company profitable. 
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